{
    "nct_id": "NCT06777979",
    "official_title": "CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic Leukemia (1922CAR)",
    "inclusion_criteria": "* Age <21 years old\n* Relapsed/refractory CD19- and/or CD22-positive acute leukemia defined as:\n\n  *CD19 and/or CD22-positivity confirmed within 2 months and after receipt of any CD19 or CD22-directed therapy\n  * Second or greater relapse\n  * Any relapse after allogeneic HCT\n  * Refractory disease (primary or in relapse) despite therapy designed to induce remission\n* Estimated life expectancy of > 12 weeks\n* Karnofsky or Lansky (age-dependent) performance score â‰¥50 (Appendix A)\n* For females of childbearing age:\n\n  * Not lactating with intent to breastfeed\n  * Not pregnant with negative serum or urine pregnancy test within 7 days prior to enrollment\nHealthy volunteers allowed\nMust have maximum age of 21 Years",
    "exclusion_criteria": "* Known primary immunodeficiency\n* Known HIV positivity\n* Known contraindication to receiving protocol defined lymphodepleting\n* chemotherapy regimen\n* History of hypersensitivity reaction to murine-containing products\n\nTreatment Eligibility\n\nInclusion Criteria:\n\n* Age < 21 years old\n* Detectable CD19- and/or CD22-positive leukemic disease in the bone marrow\n* Estimated life expectancy of > 8 weeks\n* Karnofsky or Lansky (age-dependent) performance score > 50 (Appendix A)\n* Adequate cardiac function defined as left ventricular ejection fraction >40%, or shortening fraction > 25%\n* EKG without evidence of clinically significant arrhythmia\n* Adequate renal function defined as creatinine clearance or radioisotope GFR >50 mL/min/1.73m2 (GFR >40 mL/min/1.73m2 if <2 years of age)\n* Adequate pulmonary function defined as forced vital capacity (FVC) >50% of predicted value; or pulse oximetry >92% on room air\n* Total bilirubin < 3 times the upper limit of normal for age, except in subjects with Gilbert's syndrome\n* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) < 5 times the upper limit of normal for age\n* Has recovered from all NCI CTAE grade III-IV, non-hematologic acute toxicities from prior therapy\n* Prior to planned CAR T cell infusion, patients with a history of prior allogeneicHCT must be at least 3 months from HCT, have no evidence of acute GVHD, and have not received a donor lymphocyte infusion (DLI) within the 28 daysprior to planned infusion\n* For females of childbearing age:\n\n  * Not lactating with intent to breastfeed\n  * Not pregnant with negative serum or urine pregnancy test within 7 days prior to enrollment\n  * If sexually active, agreement to use birth control until 3 months after T cell infusion. Male partners should use a condom.\n\nExclusion Criteria:\n\n* Known primary immunodeficiency\n* Known HIV positivity\n* Known contraindication to receiving protocol defined lymphodepleting\n* chemotherapy regimen\n* History of hypersensitivity reactions to murine protein-containing products\n* Severe, uncontrolled bacterial, viral or fungal infection\n* Active CNS-3 disease\n* Evidence of active, uncontrolled neurologic disease",
    "miscellaneous_criteria": "Collection and Manufacturing Eligibility"
}